Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

102.73 +0.72 (+0.71%)
Streaming Delayed Price Updated: 12:06 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 Next >
News headline image
Europe Approves Mirum Pharma's Drug For Rare Genetic Liver Disease ↗
 
Via Benzinga
News headline image
Where Mirum Pharmaceuticals Stands With Analysts ↗
Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst ratings: 
Via Benzinga
News headline image
Robinhood, MicroStrategy And Other Big Losers From Wednesday ↗
U.S. stocks closed lower on Wednesday, with the Dow Jones dipping more than 600 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
News headline image
Analysts Expect Mirum Pharma's Liver Disease Candidate Might Exceed Rival Product's Penetration ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
Recap: Mirum Pharmaceuticals Q2 Earnings ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Expert Ratings for Mirum Pharmaceuticals ↗
Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst ratings: 
Via Benzinga
News headline image
Mirum Pharma Acquires Its Licensing Partner In Cash and Stock ↗
 
Via Benzinga
News headline image
Recap: Mirum Pharmaceuticals Q1 Earnings ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday ↗
Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company. 
Via Benzinga
News headline image
'It Is Too Sizzling For Me': Why Jim Cramer Isn't Buying This 'Red Hot' Group Of Stocks ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Kelly Services, Inc. (NASDAQ: KELYA) is a "very well-run company. Right now, with people just feeling it’s easy to get a job, you don’t need them.... 
Via Benzinga
News headline image
Expert Ratings For Mirum Pharmaceuticals ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst rat... 
Via Benzinga
News headline image
Looking Into Mirum Pharmaceuticals's Return On Capital Employed ↗
According to Benzinga Pro data, during Q2, Mirum Pharmaceuticals (NASDAQ:MIRM) posted sales of $17.48 million. Earnings were up 26.45%, but Mirum Pharmaceuticals still reported an overall loss of... 
Via Benzinga
News headline image
Here's Why Mirum Pharmaceuticals Stock Is Getting Hammered ↗
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) shares are trading lower by 13.46% to $23.79 Wednesday afternoon after the company priced its common stock offering of 3.478 million shares at $23 per share.... 
Via Benzinga
News headline image
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
83 Biggest Movers From Yesterday ↗
Gainers Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results. 
Via Benzinga
News headline image
57 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
A Preview Of Mirum Pharmaceuticals's Earnings ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Mirum... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Highs On Thursday ↗
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high... 
Via Benzinga
News headline image
Earnings Scheduled For March 9, 2022 ↗
Companies Reporting Before The Bell • REV Group (NYSE:REVG) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million. • Express (... 
Via Benzinga
News headline image
Earnings Preview For Mirum Pharmaceuticals ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) is set to give its latest quarterly earnings report on Wednesday, 2022-03-09. Here's what investors need to know before the announcement.... 
Via Benzinga
News headline image
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg ↗
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
News headline image
Week In Review: Huadong Pharma Enters $662 Million Deal For Two Kiniksa Anti-Inflammatory Drugs ↗
Huadong Pharma announced a $662 million agreement to develop two Kiniksa Pharma anti-inflammatory drug candidates in southeast Asia (ex-Japan). Huadong will pay $22 million and be responsible for up to... 
Via Talk Markets
News headline image
Earnings Scheduled For November 15, 2021 ↗
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter. • Tyson Foods (NYSE:TSN) is estimated to... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More ↗
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Thursday ↗
Jefferies raised Perrigo Company plc (NYSE:PRGO) pr... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.